BioCentury
ARTICLE | Clinical News

CERC-301: Phase II started

September 7, 2015 7:00 AM UTC

Cerecor began the double-blind, placebo-controlled, U.S. Phase II Clin301-202 trial to evaluate 12 and 20 mg oral CERC-301 once weekly for 2 weeks in about 104 patients. Clin301-202 is enrolling patie...